Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1

Rhea-AI Summary

ProPhase Labs (NASDAQ: PRPH) will host an exclusive investor webinar on December 1, 2025 at 4:15 p.m. ET, hosted by RedChip Companies and featuring Chairman & CEO Ted Karkus.

The presentation will review ProPhase’s portfolio across molecular diagnostics, genomics, and consumer health, recent milestones including U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test, and a stated $7–14 billion addressable market for that test. Management will discuss a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, a streamlined cost structure, and the consumer genomics business Nebula Genomics with a large, diverse DNA dataset.

Planned near-term catalysts noted include commercialization of BE-Smart™ and expansion of DNA Complete® and DNA Expand™ product lines; a live Q&A follows. Registration is free via the RedChip webinar link.

News Market Reaction

+0.67%

3 alerts

+0.67% News Effect

+2.6% Peak Tracked

-10.5% Trough Tracked

+$56K Valuation Impact

$8M Market Cap

1.0x Rel. Volume

On the day this news was published, PRPH gained 0.67%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -10.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $56K to the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

BE-Smart addressable market: $7–14 billion COVID-19 receivables: More than $50 million Investor webinar date: December 1, 2025 at 4:15 p.m. ET

3 metrics

BE-Smart addressable market $7–14 billion Estimated market size for esophageal cancer test

COVID-19 receivables More than $50 million Targeted recovery via Crown Medical Collections initiative

Investor webinar date December 1, 2025 at 4:15 p.m. ET Scheduled RedChip-hosted investor webinar

Market Reality Check

Price: $0.2578 Vol: Volume 2,343,646 is below...

low vol

$0.2578 Last Close

Volume Volume 2,343,646 is below the 3,515,320 share 20-day average, indicating muted pre-news activity. low

Technical Shares at 0.1376 are trading below the 0.36 200-day moving average and well under the 0.9349 52-week high.

Peers on Argus

Pre-news, PRPH was down 2.62% while close diagnostics peers showed mixed moves (...

Pre-news, PRPH was down 2.62% while close diagnostics peers showed mixed moves (e.g., PRPO up 4.03%, ADVB up 6.37%, NOTV down 4.32%), pointing to stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Nov 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 26	Investor webinar	Positive	+0.7%	Announcement of December 1 investor webinar highlighting portfolio and milestones.
Nov 19	Earnings update	Negative	-9.5%	Q3 2025 results with lower revenue, net loss, tight liquidity, and strategy update.
Nov 17	Proxy reminder	Negative	-5.4%	Reminder to vote on proposals tied to strategic initiatives and Nasdaq compliance.
Oct 29	Clinical publication	Positive	-2.1%	Peer-reviewed BE-Smart study publication with strong sensitivity and risk metrics.
Oct 28	IR engagement	Positive	+2.6%	Engagement of RedChip to lead investor relations and support key initiatives.

Pattern Detected

Recent news has often aligned with price direction, though a key positive BE-Smart clinical publication saw a negative reaction, indicating occasional divergence on strong scientific updates.

Recent Company History

Over the past few months, ProPhase Labs has focused on commercializing its BE-Smart™ esophageal cancer diagnostic and strengthening investor communication. A peer-reviewed BE-Smart study with strong performance metrics was followed by engaging RedChip for investor relations and holding multiple investor events on Oct 28, Nov 19, and Nov 26, 2025. Financial filings highlighted shrinking revenue and continued losses, while emphasizing Crown Medical receivables and genomics assets. Today’s webinar-focused announcement continues this pattern of investor outreach around the BE-Smart and genomics narratives.

Market Pulse Summary

This announcement centers on an investor webinar showcasing ProPhase’s BE-Smart™ esophageal cancer t...

Analysis

This announcement centers on an investor webinar showcasing ProPhase’s BE-Smart™ esophageal cancer test, a stated $7–14 billion market opportunity, and efforts to recover more than $50 million in COVID-19 receivables. Recent filings have highlighted operating losses, tight liquidity, and significant liabilities, alongside progress in genomics and diagnostics. Investors may focus on clarity around commercialization timelines, receivables recovery, and how these initiatives relate to prior proxy approvals and capital-structure changes.

Key Terms

molecular diagnostics, genomics, clinical validation, DNA datasets

4 terms

molecular diagnostics medical

"portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

genomics medical

"assets spanning molecular diagnostics, genomics, and consumer health."

The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.

clinical validation medical

"full U.S. patent approval and clinical validation of its BE-Smart"

Clinical validation is the process of proving a medical test, device, or treatment reliably detects or predicts a health condition in real patients and settings, not just in theory or the lab. For investors it matters because successful validation lowers regulatory and adoption risk—like field-testing a new car to show it runs safely on real roads—making commercial use, reimbursement and revenue far more likely.

DNA datasets technical

"Nebula Genomics, which houses one of the world’s largest and most diverse DNA datasets."

DNA datasets are large collections of individual genetic information—like a searchable library of biological blueprints—assembled from medical tests, research studies, or consumer samples. For investors they matter because these datasets power development of new diagnostics, drugs and personalized treatments, create potential revenue through licensing or partnerships, and carry regulatory and privacy risks that can affect a company’s value and competitive edge.

AI-generated analysis. Not financial advice.

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab’s Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase’s dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approval and clinical validation of its BE-Smart^™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection in a $7–14 billion addressable market. The presentation will also cover ProPhase’s strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, its streamlined cost structure, and its consumer genomics business Nebula Genomics, which houses one of the world’s largest and most diverse DNA datasets. With multiple near-term catalysts, including the planned commercialization of BE-Smart^™ and expansion of its DNA Complete^® and DNA Expand^™ product lines, ProPhase is positioned to unlock significant shareholder value as a lean, innovation-driven healthcare company.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/PRPH/81277848610

Questions can be pre-submitted to PRPH@redchip.com or online during the live event.

About ProPhase Labs Inc.

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com.

Forward-Looking Statements

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Details about these risks and uncertainties can be found in our filings with the SEC. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Media Relations Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com

Investor Relations Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
PRPH@redchip.com

Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

FAQ

When is ProPhase Labs (PRPH) hosting the investor webinar and who will present?

The webinar is on December 1, 2025 at 4:15 p.m. ET and will feature Chairman & CEO Ted Karkus, hosted by RedChip Companies.

What key milestone will ProPhase (PRPH) discuss about the BE-Smart™ Esophageal Cancer Test?

Management will highlight U.S. patent approval and clinical validation for the BE-Smart™ Esophageal Cancer Test and its $7–14 billion addressable market estimate.

How is ProPhase Labs (PRPH) addressing COVID-19 receivables mentioned in the webinar?

The company will discuss a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables.

What consumer genomics assets will ProPhase (PRPH) cover during the presentation?

The webinar will cover Nebula Genomics, described as holding one of the world’s largest and most diverse DNA datasets, and planned expansion of DNA Complete® and DNA Expand™ products.

Will there be an opportunity to ask questions during the ProPhase (PRPH) webinar?

Yes, a live question and answer session will follow the presentation and investors can pre-submit questions to PRPH@redchip.com or ask online during the event.

How do I register for the ProPhase Labs (PRPH) December 1 webinar?

Registration is free via the RedChip webinar link provided for the event; attendees must register online to join the live presentation.